Nicole Fett

Nicole Fett

Auto-generated profile, based on publicly available information

Nicole Fett

Oregon Health and Science University, Portland, Oregon

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Clinics in Dermatology
Verified
Journal Article
Closed access
NFNicole Fett
Nicole Fett
MAMegan Arthur
Megan Arthur

1 April 2014 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
NFNicole Fett
Nicole Fett
KHKevin Haynes
Kevin Haynes
KPKathleen Joy Propert
Kathleen Joy Propert
DMDavid J. Margolis
David J. Margolis

1 May 2020 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
MAMegan Arthur
Megan Arthur
NFNicole M. Fett
Nicole M. Fett
ELEmile Latour
Emile Latour
HJHeidi Jacobe
Heidi Jacobe
EKElaine Kunzler
Elaine Kunzler
KLKelly Lo
Kelly Lo
Morphea (localized scleroderma) is a rare sclerosing disorder of the skin and subcutaneous tissue that affects patients of all ages.1-3 Patients with extensive involvement unresponsive to phototherapy, with facial involvement, or with involvement traversing joints require systemic treatment to prevent disease progression and its associated morbidity. Experts recommend treatment with methotrexate (MTX) for these patients.2-6 This recommendation is based on a randomized, double-blind, placebo-controlled clinical trial in a pediatric population comparing the combination of prednisone for 3 months and MTX for 12 months vs prednisone alone for 3 months.7 Those who received MTX demonstrated improved skin scores and were less likely to experience disease relapse compared with those who received placebo. In addition, several small retrospective studies and a prospective study have further supported the value and safety of MTX, with or without systemic corticosteroids (SCSs), for the treatment of morphea.8-15 For some patients, treatment with MTX is ineffective, not well tolerated, or contraindicated. Studies suggest that approximately 25% to 30% of patients with morphea will not show clinical improvement with MTX.7,12 In this subset of patients, a trial of mycophenolate mofetil (MMF) or mycophenolic acid (MPA)—referred to herein as mycophenolate—is recommended, although evidence supporting this practice is based on small case series.2,4,5

6 May 2019 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
CHCarter K. Haag
Carter K. Haag
AOAlex G. Ortega-Loayza
Alex G. Ortega-Loayza
ELEmile Latour
Emile Latour
JKJesse J. Keller
Jesse J. Keller
NFNicole M. Fett
Nicole M. Fett
Background: Pyoderma gangrenosum (PG) is a neutrophilic disorder which classically presents as chronic, painful ulcers on the lower extremities. There is evidence supporting a potential role for intravenous immunoglobulin (IVIG) as adjuvant therapy for treatment-resistant cases; however, it is unclear which patients will most benefit from this modality of treatment – an especially important consideration given the cost per infusion ($5,000-$10,000). Thus, we sought to identify the clinical characteristics of patients with refractory PG lesions who demonstrated complete healing when IVIG was incorporated into the therapeutic plan. Methods: We performed a literature search of PubMed/MEDLINE and Embase using the keywords “pyoderma gangrenosum” and “IVIG”. We also added four institutional cases. Descriptive statistics were used to analyze the data. Significance was set at p < 0.05. Results: We discovered a total of 45 cases. Twenty-three patients with treatment-resistant PG had complete healing, 22 had partial or unhealed PG ulcers. Patients with one ulcer were 4.1 (95% CI: 1.1 to 18.5) times more likely to achieve complete healing than patients with more than one ulcer, when IVIG was added (p = 0.041). Conclusion: There is increased efficacy of IVIG as a treatment for patients with a solitary treatment-resistant PG lesion compared to patients with multiple refractory lesions.

12 December 2023 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
NTNoelle Teske
Noelle Teske
NFNicole Fett
Nicole Fett

1 May 2016 in Journal of Dermatological Science
Verified
Journal Article
Closed access
NFNicole Fett
Nicole Fett
KHKevin Haynes
Kevin Haynes
KPKathleen Joy Propert
Kathleen Joy Propert
DMDavid J. Margolis
David J. Margolis